Results 31 to 40 of about 49,177 (212)

“Clozapine & Valbenazine for Treatment of Tardive Cervical Dystonia: A Case Report”

open access: yesTranslation, 2023
Cervical dystonia is a subtype of tardive dyskinesia characterized by smooth, sustained muscle contractions affecting the head, neck, and shoulders. This condition can be caused by antipsychotic medication exposure.
Chandani Lewis, Christine Brennan
doaj   +1 more source

Cortical Thickness and White Matter Surface Morphology in Tourette Syndrome: A Cohort Study

open access: yesAnnals of Neurology, EarlyView.
Objective To examine cortical thickness and white matter surface morphology in a large sample of individuals with Tourette syndrome (TS) and neurotypical controls across the lifespan, and to assess associations with symptom severity, comorbidities, and medication use.
Sahar Delavari   +8 more
wiley   +1 more source

Probable respiratory dyskinesia in an elderly patient after sudden stoppage of antipsychotics

open access: yesJournal of Geriatric Mental Health, 2016
Antipsychotic drugs are widely used in the management of schizophrenia in the elderly. Extrapyramidal reactions to these drugs and tardive dyskinesia are a dreaded side effect of these drugs that may be seen in the elderly. We present herewith, a case of
Vikram Vaidya   +2 more
doaj   +1 more source

Tardive Dyskinesia and Dystonia – Clinical Case Review and Grand Rounds

open access: yesJournal of Psychiatry Spectrum, 2022
Tardive dyskinesia (TD) syndromes are clinical conditions characterized by abnormal involuntary movements of the body and can range from occasional annoying involuntary movements to debilitating dystonia and are associated with increased mortality rates ...
Satish Suhas   +3 more
doaj   +1 more source

Acute and Chronic Local Field Potential Recordings in Dystonia—A Systematic Review

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Dystonia is a hyperkinetic movement disorder increasingly conceptualized as a disorder of distributed network dysfunction involving the basal ganglia, cortex and cerebellum. Local field potentials (LFPs) recorded from deep brain stimulation (DBS) electrodes provide a unique opportunity to characterize the electrophysiological signatures ...
Jack Horan   +6 more
wiley   +1 more source

Explore the Mechanism of Xiaoyaosan for Treatment of Bipolar Disorder Based on Network Pharmacology, Experimental Validation and Molecular Docking

open access: yesCNS Neuroscience &Therapeutics, Volume 32, Issue 10, October 2026.
This study evaluates Xiaoyaosan (XYS) for bipolar disorder (BD) using network pharmacology and experimental validation. Molecular docking reveals interactions between active XYS compounds and potential core targets. Animal experiments confirm XYS alleviates BD‐like behaviors in mice by suppressing core targets, elucidating its multi‐target mechanism ...
Man Chen   +10 more
wiley   +1 more source

Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia

open access: yes, 2018
Background: Tardive dyskinesia (TD) is a disabling movement disorder associated with the prolonged use of antipsychotic medication. Several strategies have been examined in the treatment of TD.
Rathbone, John   +8 more
core   +1 more source

Improvement of tardive dyskinesia after switching from zuclopenthixol decanoate to paliperidone palmitate: a case report [PDF]

open access: yesDüşünen Adam Psikiyatri ve Nörolojik Bilimler Dergisi, 2014
Long-acting injectable (LAI) antipsychotics are an effective option in schizophrenia that increase treatment adherence in potentially non-compliant patients.
eren yildizhan   +2 more
doaj  

Lurasidone-induced tardive dyskinesia

open access: yesAnnals of Indian Psychiatry, 2022
Lurasidone is a novel atypical antipsychotic with additional antidepressant and pro-cognitive properties. The drug has shown good efficacy in treatment of schizophrenia as well as bipolar disorder.
Shreyas Shrikant Pendharkar   +1 more
doaj   +1 more source

Gastrointestinal adverse effects of GLP‐1 receptor agonists and dual GIP/GLP‐1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents

open access: yesNutrition in Clinical Practice, Volume 41, Issue 5, Page 1318-1333, October 2026.
Abstract Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1 receptor agonists have transformed the management of type 2 diabetes and obesity. Gastrointestinal (GI) adverse events are the most common limitation of these therapies and a leading cause of discontinuation ...
Vikash Singhani   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy